Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.45 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116157 | 0.99 | PTPN5 (0.44) | PTPN5P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL3417230 | 0.85 | TMPRSS4 (0.44) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL3420560 | 0.81 | AKR1C2 (0.47) | P2RX1TMPRSS4P2RX4P2RX7AKR1C3 | |
| SCHEMBL28549936 | 0.80 | KDM4E (0.49) | P2RX1TMPRSS4P2RX4P2RX7KDM4E | |
| SCHEMBL10298077 | 0.79 | ALDH1A1 (0.52) | MEN1KMT2AMAPTAKR1C3AKR1C2 | |
| SCHEMBL12877141 | 0.76 | KDM4C (0.53) | PTPN5KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL29390264 | 0.74 | KDM4C (0.69) | P2RX1TMPRSS4P2RX4P2RX7KDM4E | |
| SCHEMBL607106 | 0.74 | KDM4C (0.69) | P2RX1TMPRSS4P2RX4P2RX7KDM4E | |
| SCHEMBL130628 | 0.74 | ALDH1A1 (0.59) | TMPRSS4KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL1226636 | 0.73 | KDM4C (0.50) | PTPN5KDM4EMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | claimed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | claimed |
| EP-2004164-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2018-08-08 | — | — | EP | disclosed |
| US-8598383-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2013-12-03 | — | — | US | disclosed |
| US-20130316988-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2013-11-28 | — | — | US | disclosed |
| US-8455470-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD (KR) | 2013-06-04 | — | — | US | disclosed |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-11-29 | — | — | US | disclosed |
| US-20120209025-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GWAG BYOUNG-JOO (KR) | 2012-08-16 | — | — | US | disclosed |
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | disclosed |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GNT PHARMA CO., LTD. (KR) | 2009-11-12 | — | — | US | disclosed |
| US-20090240079-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-09-24 | — | — | US | disclosed |
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-06-11 | — | — | US | disclosed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | disclosed |
| EP-2004164-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | Neurotech Co., Ltd. (KR) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007119973-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | NEUROTECH CO., LTD. (KR) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | PTPN5 4647/4885P2RX1 4068/4885TMPRSS4 4060/4885 |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | PTPN5 4647/4885P2RX1 4068/4885TMPRSS4 4060/4885 |
| US-20120209025-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | PTPN5 2408/4885P2RX1 1254/4885TMPRSS4 3534/4885 |
| US-20090240079-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | PTPN5 2408/4885P2RX1 1254/4885TMPRSS4 3534/4885 |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | PTPN5 2408/4885P2RX1 1254/4885TMPRSS4 3534/4885 |
| US-20130316988-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | PTPN5 2408/4885P2RX1 1254/4885TMPRSS4 3534/4885 |
| US-20100216749-A1 | Combination Therapy for Neuroprotection | MPO, BDNF, NLN | PTPN5 3990/4885P2RX1 1509/4885TMPRSS4 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.